Edition:
United States

MediciNova Inc (4875.T)

4875.T on Tokyo Stock Exchange

826JPY
7:26pm EST
Change (% chg)

¥24 (+2.99%)
Prev Close
¥802
Open
¥810
Day's High
¥827
Day's Low
¥806
Volume
79,000
Avg. Vol
121,023
52-wk High
¥1,100
52-wk Low
¥414

4875.T

Chart for 4875.T

About

MediciNova, Inc. is a biopharmaceutical company. The Company is focused on acquiring and developing small molecule therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States market. It is focused on its development activities on MN-166 (ibudilast) for neurological... (more)
No analyst recommendations are available for 4875.T.

Overall

Beta: 0.73
Market Cap(Mil.): ¥28,190.26
Shares Outstanding(Mil.): 34.49
Dividend: --
Yield (%): --

Financials

  4875.T Industry Sector
P/E (TTM): -- 42.21 29.87
EPS (TTM): -42.49 -- --
ROI: -31.28 -1.09 14.95
ROE: -34.54 -2.39 16.29

BRIEF-Medicinova files for offering of up to 869,047 shares by selling stockholders

* Files for offering of up to 869,047 shares of common stock by the selling stockholders

Nov 29 2016

BRIEF-Medicinova Inc - expected basic, diluted loss per share for year ending Dec. 31 is $0.31

* Medicinova Inc - expected basic and diluted loss per share for year ending December 31, 2016 is $0.31 Source text (http://bit.ly/2e9YebC) Further company coverage:

Oct 26 2016

BRIEF-MediciNova sees loss per share for year ending Dec 31 of $0.31

* Says expected loss per share for year ending December 31, 2016 is $0.31

Jul 27 2016

BRIEF-MediciNova receives notice of allowance for new patent covering MN-001 and MN-002 for the treatment of fibrosis

* Says it received a notice of allowance from the U.S. Patent And Trademark Office (Uspto) for a pending patent application which covers Mn-001 (Tipelukast) and Mn-002 (A Major Metabolite Of Mn-001) for the treatment of "Fibrosis" which includes a broad range of fibrosis / fibrotic disease in different organs due to different causes

Jul 26 2016

BRIEF-Medicinova starts interim efficacy analysis in phase 2b trial of MN-166

* Medicinova announces initiation of interim efficacy analysis in phase 2b trial of MN-166 (ibudilast) in progressive MS

Jul 13 2016

BRIEF-Medicinova added to Russell 3000  Index and Russell Global Index

* Company has been added to Russell 3000  Index and Russell Global Index as a result of annual Russell Index reconstitution

Jun 26 2016

Earnings vs. Estimates